Atorvastatin/fenofibrate

Drug Profile

Atorvastatin/fenofibrate

Alternative Names: AtorFen; LCP-AtorFen

Latest Information Update: 09 Feb 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator LifeCycle Pharma
  • Developer Athena Drug Delivery Solutions; LifeCycle Pharma; Veloxis Pharmaceuticals
  • Class Antihyperlipidaemics; Butyric acids; Fluorobenzenes; Heptanoic acids; Propionates; Pyrroles; Small molecules
  • Mechanism of Action HMG-CoA reductase inhibitors; Peroxisome proliferator-activated receptor alpha agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes - Hyperlipidaemia

Highest Development Phases

  • No development reported Dyslipidaemias

Most Recent Events

  • 29 Dec 2011 Atorvastatin/fenofibrate is available for sublicensing as of 29 Dec 2011. http://www.athenadiagnostics.com/content/about/
  • 23 Dec 2011 Clinical trials in Dyslipidaemia in emerging markets (PO)
  • 08 Jul 2011 Suspended - Phase-II/III for Dyslipidaemia in USA (PO); Veloxis seeks partnership opportunities
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top